Consun Pharmaceutical Group Ltd. (1681) Price & Analysis

Compare

7 Followers

1681 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$6.86 - HK$16.86

Previous CloseN/A

Volume1.82M

Average Volume (3M)4.50M

Market Cap

€13.31B

Enterprise ValueHK$5.87B

Total Cash (Recent Filing)€3.87B

Total Debt (Recent Filing)€267.17M

Price to Earnings (P/E)12.4

Beta0.48

Next Earnings

Apr 01, 2026

EPS EstimateN/A

Last Dividend Ex-Date

Sep 04, 2025

Dividend Yield3.94%

Share Statistics

EPS (TTM)0.63

Shares Outstanding852,865,700

10 Day Avg. Volume4,522,779

30 Day Avg. Volume4,496,214

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€21.98

Price Target Upside37.66% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Dividend And YieldDividend payout increased by 10ppts to 51% in 2024, with the higher payout expected to continue given solid financial position, translating into an attractive yield of 7%+.

Earnings And Financial PerformanceFY24 earnings up 16% to Rmb910m, mainly driven by volume growth in uremic clearance granules.

Market AccessThe number of provinces that eliminated UCG sales restrictions rose from 22 to 25, indicating a broader market access.

Bears Say

Economic ConditionsThere is a slowdown in sales volume growth due to a slowing economy.

Sales GrowthSales volume growth slowdown due to a slowing economy.

Consun Pharmaceutical Group Ltd. News

Consun Pharmaceutical Group Redesignates Professor Zhu Quan as Non-Executive Director

Consun Pharmaceutical Group Ltd. ( ($HK:1681) ) has issued an update. Consun Pharmaceutical Group Ltd. announced the redesignation...

5d ago

Consun Pharmaceutical Group Announces Board Composition and Committee Roles

Consun Pharmaceutical Group Ltd. ( ($HK:1681) ) has issued an update. Consun Pharmaceutical Group Ltd. has announced the...

5d ago

Consun Pharmaceutical Reports Strong Interim Financial Results for 2025

Consun Pharmaceutical Group Ltd. ( ($HK:1681) ) just unveiled an announcement. Consun Pharmaceutical Group Ltd. reported a significant...

1M ago

Consun Pharmaceutical Group Announces Upcoming Board Meeting to Discuss Interim Results

Consun Pharmaceutical Group Ltd. ( ($HK:1681) ) has provided an update. Consun Pharmaceutical Group Ltd. has scheduled a...

2M ago

Consun Pharmaceutical Group Engages in Significant Wealth Management Subscriptions

Consun Pharmaceutical Group Ltd. ( ($HK:1681) ) has shared an update. Consun Pharmaceutical Group Ltd. has announced that...

2M ago

Consun Pharmaceutical Group Announces Board Composition and Committee Roles

Consun Pharmaceutical Group Ltd. ( ($HK:1681) ) has provided an update. Consun Pharmaceutical Group Ltd. has announced the...

3M ago

Consun Pharmaceutical Group Ltd. Forms Nomination Committee to Strengthen Governance

The latest announcement is out from Consun Pharmaceutical Group Ltd. ( ($HK:1681) ). Consun Pharmaceutical Group Ltd. has...

3M ago

Consun Pharmaceutical Group Updates Nomination Committee for Enhanced Governance

An update from Consun Pharmaceutical Group Ltd. ( ($HK:1681) ) is now available. Consun Pharmaceutical Group Ltd. announced...

3M ago

Consun Pharmaceutical Launches HKD200 Million Share Repurchase Program

Consun Pharmaceutical Group Ltd. ( ($HK:1681) ) has provided an update. Consun Pharmaceutical Group Ltd. has announced a...

4M ago

Consun Pharmaceutical Successfully Passes AGM Resolutions

Consun Pharmaceutical Group Ltd. ( ($HK:1681) ) just unveiled an announcement. Consun Pharmaceutical Group Ltd. announced the successful...

4M ago

1681 FAQ

What was Consun Pharmaceutical Group Ltd.’s price range in the past 12 months?

Consun Pharmaceutical Group Ltd. lowest stock price was HK$6.86 and its highest was HK$16.86 in the past 12 months.

What is Consun Pharmaceutical Group Ltd.’s market cap?

Consun Pharmaceutical Group Ltd.’s market cap is €13.31B.

When is Consun Pharmaceutical Group Ltd.’s upcoming earnings report date?

Consun Pharmaceutical Group Ltd.’s upcoming earnings report date is Apr 01, 2026 which is in 183 days.

How were Consun Pharmaceutical Group Ltd.’s earnings last quarter?

Consun Pharmaceutical Group Ltd. released its earnings results on Aug 19, 2025. The company reported HK$0.635 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.635.

Is Consun Pharmaceutical Group Ltd. overvalued?

According to Wall Street analysts Consun Pharmaceutical Group Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Consun Pharmaceutical Group Ltd. pay dividends?

Consun Pharmaceutical Group Ltd. pays a Quarterly dividend of HK$0.33 which represents an annual dividend yield of 3.94%. See more information on Consun Pharmaceutical Group Ltd. dividends here

What is Consun Pharmaceutical Group Ltd.’s EPS estimate?

Consun Pharmaceutical Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Consun Pharmaceutical Group Ltd. have?

Consun Pharmaceutical Group Ltd. has 852,865,700 shares outstanding.

What happened to Consun Pharmaceutical Group Ltd.’s price movement after its last earnings report?

Consun Pharmaceutical Group Ltd. reported an EPS of HK$0.635 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 10.385%.

Which hedge fund is a major shareholder of Consun Pharmaceutical Group Ltd.?

Currently, no hedge funds are holding shares in HK:1681

Consun Pharmaceutical Group Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

25.92%

Trailing 12-Months

Asset Growth

2.75%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Consun Pharmaceutical Group Ltd.

Consun Pharmaceutical Group Ltd. (1681) is a China-based pharmaceutical company engaged in the research, development, manufacturing, and marketing of modern Chinese medicines and medical contrast medium products. The company primarily focuses on nephrology, orthopedics, and dermatology sectors, providing a diverse range of therapeutic solutions aimed at addressing specific medical needs. Consun Pharmaceutical is recognized for its innovation in traditional Chinese medicine formulations, integrating modern scientific approaches to enhance efficacy and safety.

Consun Pharmaceutical Group Ltd. (1681) Earnings & Revenues

Historic Earnings Reports

1681 Stock 12 Month Forecast

Average Price Target

HK$21.98

▲(37.66% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"HK$2","7":"HK$7","12":"HK$12","17":"HK$17","22":"HK$22"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.99999999671232,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.9846381168,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$21.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.99999999671232,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,7,12,17,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.709,15.269846153593255,15.83069230718651,16.391538460779767,16.95238461437302,17.513230767966277,18.07407692155953,18.634923075152788,19.19576922874604,19.756615382339298,20.31746153593255,20.87830768952581,21.439153843119065,{"y":21.99999999671232,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.709,15.268664470523076,15.828328941046154,16.38799341156923,16.947657882092308,17.507322352615382,18.06698682313846,18.62665129366154,19.186315764184613,19.74598023470769,20.30564470523077,20.865309175753843,21.42497364627692,{"y":21.9846381168,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.709,15.269846153593255,15.83069230718651,16.391538460779767,16.95238461437302,17.513230767966277,18.07407692155953,18.634923075152788,19.19576922874604,19.756615382339298,20.31746153593255,20.87830768952581,21.439153843119065,{"y":21.99999999671232,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.971,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.258,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.667,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.667,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.453,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.037,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.769,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.464,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.626,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.276,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.078,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.192,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.709,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >